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http://dx.doi.org/10.1016/j.ccr.2012.06.027SUMMARYHomeobox domain-containing transcription factors are important regulators of hematopoiesis. Here, we
report that increased levels of nonclustered H2.0-like homeobox (HLX) lead to loss of functional hematopoi-
etic stem cells and formation of aberrant progenitors with unlimited serial clonogenicity and blocked
differentiation. Inhibition of HLX reduces proliferation and clonogenicity of leukemia cells, overcomes the
differentiation block, and leads to prolonged survival. HLX regulates a transcriptional program, including
PAK1 and BTG1, that controls cellular differentiation and proliferation. HLX is overexpressed in 87% of
patients with acute myeloid leukemia (AML) and independently correlates with inferior overall survival
(n = 601, p = 2.33 106). Our study identifies HLX as a key regulator in immature hematopoietic and leukemia
cells and as a prognostic marker and therapeutic target in AML.INTRODUCTION
Transcription factors are critical for the regulation of normal
hematopoiesis as well as leukemogenesis (Friedman, 2007;
Laiosa et al., 2006; Tenen, 2003). Several members of the Hox
(class I homeobox genes) family of transcription factors, which
contain a conserved homeobox domain and are organized into
four major gene clusters in humans, have been implicated in
the functioning of hematopoietic stem and progenitor cells
(HSPC) as well as in leukemic transformation and the generation
of leukemia-initiating cells (Argiropoulos and Humphries, 2007;
Krumlauf, 1994; Sitwala et al., 2008). Less is known about the
role of nonclustered (class II) homeobox genes in hematopoiesis
and leukemia. Members of the CDX family, for instance, have
been found to be overexpressed in acute leukemias and to regu-Significance
AML is a heterogeneous disease with poor clinical outcome. Le
current treatment regimens, and prognostication and risk strat
targets are desired for more effective therapeutic intervention
regulator in immature hematopoietic and leukemia cells. HLX
high levels ofHLX correlate with inferior survival. Inhibition of H
survival in an in vivo model. As a key factor controlling maligna
and therapeutic target in AML and possibly other types of can
194 Cancer Cell 22, 194–208, August 14, 2012 ª2012 Elsevier Inc.lateHox gene expression (Bansal et al., 2006; Scholl et al., 2007).
Transcriptional analysis of purified stem and progenitor popula-
tions has recently been utilized as a powerful tool to identify
critical regulators of stem and progenitor cell function and
transformation to leukemia-initiating cells (Krivtsov et al., 2006;
Majeti et al., 2009; Passegue´ et al., 2004; Saito et al., 2010;
Somervaille and Cleary, 2006; Steidl et al., 2006, 2007). Our anal-
ysis of preleukemic HSPC in amurinemodel of AML revealed the
nonclustered H2.0-like homeobox (Hlx) gene to be 4-fold upre-
gulated compared to wild-type (WT) HSPC (Steidl et al., 2006;
data not shown), suggesting that Hlx may be involved in malig-
nant transformation. HLX is the highly conserved human-murine
homolog of the homeobox gene H2.0, which shows tissue-
specific expression throughout development in Drosophila
melanogaster (Allen et al., 1991; Hentsch et al., 1996). Additionalss than one third of patients achieve durable remission with
ification of individual patients is challenging. New molecular
. We identify the nonclustered homeobox gene Hlx as a key
is overexpressed in the majority of patients with AML, and
LX overcomes the differentiation block of AML and prolongs
nt cell growth and differentiation, HLXmay be a prognostic
cer.
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HLX Regulates Early Hematopoiesis and Promotes AMLstudies two decades ago detected HLX expression in hemato-
poietic progenitors and in leukemic blasts of patients with
AML, and a study of HLX-deficient fetal liver cells suggested
a decrease of colony-formation capacity (Deguchi and Kehrl,
1991; Deguchi et al., 1992). However, the precise function of
HLX in HSPC and its role in leukemia have not been studied,
which was the objective of the present study. AML is a heteroge-
neous diseasewith overall poor clinical outcome (Marcucci et al.,
2011). Less than one third of patients with AML achieve durable
remission with current treatment regimens. Furthermore, prog-
nostication and risk stratification of individual patients remains
very challenging, in particular in favorable and standard risk
groups. New targets need to be identified for effective and indi-
vidualized therapeutic intervention.
RESULTS
HLX Overexpression Impairs Hematopoietic
Reconstitution and Leads to a Decrease in Long-Term
Hematopoietic Stem Cells and Persistence of a Small
Progenitor Population
To examine the functional consequences of elevated HLX levels
on hematopoiesis, we sorted lineage-negative (Lin), Kit+ bone
marrow (BM) cells from Ly5.2(CD45.2)+ WT mice, transduced
them with a lentivirus expressing HLX and GFP, or GFP alone
as a control (Figures 1A and 1B), and transplanted them into
lethally irradiated congenic Ly5.1(CD45.1)+ recipient mice.
Transduction efficiency of control lentivirus and Hlx lentivirus
was comparable, with both at approximately 50% (see Fig-
ure S1A available online). Twenty-four hours after transplanta-
tion, both control and HLX-overexpressing GFP+ Ly5.2+ donor
cells were detected in the BM at similar frequencies (42.8%
and 41.6%, respectively) (Figure 1C), indicating equal homing
of the transplanted cells. Twelve weeks after transplantation,
we evaluated hematopoietic multilineage reconstitution in the
peripheral blood. Both groups engrafted robustly with an
average donor chimerism of Ly5.2 cells of 80% (SD: 10%) and
85% (SD: 9%) in the control and Hlx groups, respectively.
However, although mice transplanted with control cells showed
35% (SD: 17%) GFP+ cells in the peripheral blood 12 weeks after
transplantation, mice transplanted with Hlx-transduced cells
displayed drastically fewer GFP+ cells, with only 0.07% (SD:
0.06%), demonstrating a severe defect of HLX-overexpressing
cells in hematopoietic reconstitution (Figure 1D). To determine
the cellular compartments in which HLX was effective, we
analyzed stem and progenitor cells in recipient BM. No GFP+
long-term hematopoietic stem cells (LT-HSC; Thy1loFlk2-LSK
[LinSca1+Kit+]) in mice transplanted with HLX-expressing cells
were detected, whereas control mice displayed, on average,
42% (SD: 20%) GFP+ LT-HSC (Figure 1E). Furthermore, in
contrast to control animals, we could not find any GFP+ HLX-
expressing short-term HSC (ST-HSCs; Thy1loFlk2+LSK), multi-
potent progenitors (MPP; Thy1 Flk2+LSK), common myeloid
progenitors (CMP; LinKit+Sca-1FcgRII/IIIloCD34lo), granulo-
cyte-monocyte progenitors (GMP; LinKit+Sca-1FcgRII/III+
CD34+). or megakaryocyte-erythrocyte progenitors (MEP;
LinKit+Sca-1FcgRII/III-CD34), indicating that HLX acts at
the level of the earliest hematopoietic stem cells (Figure S1B).
When we analyzed Hlx-GFP-transduced LinKit+ (KL) cells byAnnexinV/DAPI staining, both control and HLX-overexpressing
cells displayed the same low percentage of apoptotic-necrotic
cells (Figure S1C), indicating that HLX acts by a mechanism
other than induction of apoptosis or necrosis. Further analysis
for donor-derived cell populations persisting upon HLX overex-
pression revealed a small population of GFP+, CD45.2(Ly.5.2)+,
Lin, CD34, and Kit cells, which were still present in the BM
12weeks after transplantation (Figure 1F). Analysis for additional
surface markers revealed that these cells were characterized by
intermediate expression of CD11b, as well as high expression
of CD49b and CD44 (Figure 1G, left panel), which is consistent
with the surface phenotype of myeloid precursor cells slightly
past the GMP stage (Novershtern et al., 2011). This CD45+
CD11bmidCD49b+CD44+ cell population was 16-fold expanded
upon HLX expression in comparison to control (p = 1.1 3 105)
(Figure 1G, right panel).
HLX Confers Unlimited Serial Clonogenicity
to CD34–Kit– Hematopoietic Cells
Next, we performed in vitro colony formation assays of trans-
duced LSK cells. Hlx-transduced LSK cells formed slightly fewer
and smaller colonies than did control-transduced LSK cells in the
initial plating (Figure 2A, left panel, and Figure S2A). To evaluate
long-term clonogenic potential of HLX-overexpressing cells, we
performed serial-replating assays. LSK cells overexpressing
HLX showed greater clonogenic capacity in the second to fifth
plating, in comparison to control-transduced cells, and main-
tained serial replating capacity through the sixth to ninth plating
(Figure 2A, right panel), showing a de facto immortalization of this
clonogenic progenitor population by HLX. In addition, colonies
were noticeably larger in size after five platings compared to
control (Figure 2B). Analysis of cells isolated from the initial
plating revealed that HLX overexpression led to a decrease of
Kit+ cells, similar to the in vivo phenotype, and an increased
proportion of phenotypically more mature CD34Kit cells in
comparison to control-transduced cells (Figure 2C). To further
characterize this persisting population, we examined a panel of
cell surface markers. Although the CD34Kit cells were nega-
tive for CD11c, CD25, FcgRII/III, CD61, CD115, and CD150 (Fig-
ure S2B; and data not shown), they expressedCD49b andCD44,
as well as intermediate levels of CD11b (Figure S2B), similar to
our observations in vivo (Figure 1G). To determine which cellular
subpopulation conferred the increased clonogenic capacity,
we sorted equal numbers of CD34+Kit+ cells, CD34+Kit cells,
CD34Kit+ cells, and CD34Kit cells from the first plating (pop-
ulations I–IV, see Figure 2C), and subjected each individual pop-
ulation to colony formation assays. Only CD34Kit cells derived
from HLX-overexpressing cells formed a larger number of colo-
nies in comparison to control cells, whereas all other populations
did not display significant clonogenicity (Figure 2D). Further-
more, the HLX-overexpressing GFP+CD34Kit cells showed
serial replating capacity through four rounds, whereas all other
populations exhausted significantly earlier (Figure 2E). Finally,
when we injected HLX-overexpressing GFP+CD34Kit cells
from the fourth, sixth, or eighth plating into irradiated NOD-
SCID-IL2Rgamma null (NSG) mice, GFP+ cells were detectable
after 7 weeks in the peripheral blood (Figure S2C; and data not
shown). These data indicate that increased levels of HLX confer
long-term clonogenicity to a population of CD34Kit cells.Cancer Cell 22, 194–208, August 14, 2012 ª2012 Elsevier Inc. 195
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Figure 1. HLX Overexpression Impairs Hematopoietic Reconstitution and Leads to a Decrease in Long-Term Hematopoietic Stem Cells and
Persistence of a Small Progenitor Population
(A) Schematics of lentiviral vectors.
(B) Increased protein expression of HLX in LinKit+ cells after transduction with HLX-expressing lentivirus and sorting of GFP+ cells.
(C) Homing is not affected by HLX overexpression. Lentivirus-transduced LinKit+ cells (8 3 104) from WT C57BL/6 mice (Ly5.2) were transplanted into lethally
irradiated congenicWT recipients (Ly5.1). Bonemarrowmononuclear cells from recipients were analyzed 24 hr after transplantation. The frequency of GFP+ cells
in the donor population (Ly5.1Ly5.2+) was assessed, and averages ± SD are shown (n = 3).
(D and E) Control- or Hlx-IRES-GFP-transduced Lin-Kit+ cells (Ly5.2) together with spleen cells from congenic WT mice (Ly5.1) were transplanted into lethally
irradiated congenic WT recipients (Ly5.1) (n = 7) and analyzed 12 weeks after transplantation. Total GFP+ cells in peripheral blood (D) and LinKit+Sca+
Thy1loFlk2 LT-HSC in bone marrow (E) are shown. Detailed gating scheme and additional analyses are shown in Figure S1. Means are indicated by horizontal
lines in the panels on the right.
(F) Analysis of GFP+ cells in total bonemarrow cells from recipients transplanted withHlx-transduced LinKit+ cells after 12 weeks. Relative percentages of GFP+,
Lin, as well as CD34Kit donor cells are indicated.
(G) CD49b, CD11b, and CD44 expression on donor Ly5.2+GFP+LinKit cells from recipients transplanted withHlx- or control-transduced LinKit+ cells 6 weeks
after transplantation. Representative histogram plots are shown on the left. Percentage of Ly5.2+GFP+LinKit cells that coexpress CD49b+, CD11bmid, and
CD44+ are displayed for the control and Hlx groups in the right panel (n = 4/condition).
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Figure 2. HLX Overexpression Confers Serial Replating Capacity to Lin–CD34–Kit– Cells
(A) Primary colony formation assay (left panel) and serial replating assay (right panel) of LinKit+Sca1+ cells after transduction with control lentivirus or Hlx
lentivirus. GFP+ colonies derived from control cells (white bars) and HLX-overexpressing cells (black bars) ± SD are shown. Statistical significance is indicated
(*p < 0.05, and **p < 0.005, n = 3).
(B) Photograph of entire tissue culture dishes after fifth plating shows enlarged size of colonies derived from the Hlx-transduced cells. Scale bar
indicates 1 cm.
(C) HLX overexpression leads to a decrease of CD34+Kit+ cells and increases the CD34Kit population. Representative FACS plots are shown in the upper
panel. The lower panel shows the frequency of each population within total GFP+ cells (I = CD34+Kit+, II = CD34+Kit, III = CD34Kit+, and IV = CD34Kit). Means
of control cells (white bars) and HLX-overexpressing cells (black bars) (± SD) are shown. Statistical significance is indicated (*p < 0.05, n = 3).
(D) Whole plate photographs of colonies derived from sorted cells from each population (I, II, III, and IV). Scale bars indicate 1 cm.
(E) Serial replating assay of each sorted population (I, II, III, and IV). Colony numbers (± SD) after second plating (white bars), third plating (gray bars), and fourth
plating (black bars) are shown (n = 3). Statistical significance is indicated (*p = 0.013; **p = 0.0015; ***p = 0.0004). Additional data on the aberrant clonogenic
population is shown in Figure S2.
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To investigate the effect of HLX overexpression on differentiation
capacity, we analyzed the clonogenic GFP+CD34Kit cells
from the first colony assay for the expression of additional cell
surface markers. The proportions of Gr1+Mac1+-, Gr1Mac1+-,
and F4/80+Mac1+-expressing cells were significantly reduced
(Gr1+Mac1+: from 29.7% [control] [SD: 6.6%] to 16.2% [Hlx]
[SD: 1.9%], p = 0.026; Gr1Mac1+: from 30.7% [SD: 4.5%]
to 11.2% [SD: 2.6%], p = 0.003; F4/80+Mac1+: from 31.6%
[SD: 4.9%] to 8.9% [SD: 2.8%], p = 0.002; n = 3), indicative of
a defect in myelomonocytic differentiation (Figure 3A). Expres-
sion of erythroid, B-lymphoid, and T-lymphoid markers was
unchanged. Furthermore, almost half of the HLX-overexpressing
GFP+CD34Kit population (47.6% [SD: 2.8%]) was lineage-
negative, in contrast to only 17% (SD: 1.2%) of GFP+CD34Kit
control-transduced cells (p = 0.005) (Figure 3A). Sorted, HLX-
overexpressing GFP+LinCD34Kit cells also showed a
significant increase in clonogenicity compared with control-
transduced cells (Figure S3), indicating that HLX acts at the level
of LinCD34Kit cells. To specifically test myelomonocytic
differentiation, we carried out colony-formation assays with
GM-CSF or M-CSF stimulation (Figures 3B–3E). Hlx-transduced
cells gave rise to lower numbers of Gr1Mac1+ and F4/
80+Mac1+ cells, compared to control-transduced cells, upon
either GM-CSF or M-CSF stimulation (Figures 3B and 3D). Cyto-
morphological evaluation of cells after stimulation showed an
increased percentage of Hlx-transduced cells with immature
progenitor morphology, in stark contrast to control-transduced
cells which predominantly displayed mature monocytic
morphology (Figures 3C and 3E). Taken together, our findings
show that HLX not only enhances clonogenicity of an increased
population of LinCD34Kit cells, but also confers a partial
myelomonocytic differentiation block.
HLX Downregulation Inhibits AML
To test whether HLX overexpression is functionally important for
AML, we targeted Hlx by RNA interference. We transduced
leukemia cells derived from the PU.1 URED/D AML model (URE
cells) as well as human AML cells with lentiviral constructs ex-
pressing either Hlx-directed (sh Hlx) or control shRNA (sh
control). Knockdown of HLX by 80% led to significantly reduced
cell proliferation in suspension culture, as well as reduced forma-
tion of colonies of URE cells in methylcellulose assays in
comparison to control cells (p < 0.00001) (Figures 4A–4C). Like-
wise, human KG1a, THP1, and MOLM13 AML cells showed
40%–60% reduced growth (p = 0.003, p = 0.001, and p =
0.015, respectively) in suspension culture, as well as significantly
diminished clonogenicity (p = 0.02, p = 0.038, and p = 0.004,
respectively) (Figure 4D). To test the antileukemic effect of
HLX suppression in vivo, we performed murine transplanta-
tion assays. We found that reduction of HLX levels in trans-
planted URE cells significantly prolonged recipient survival in
comparison to mice transplanted with control shRNA-trans-
duced cells (p = 0.0012, and p = 0.0041) (Figure 4E). Taken
together, our findings demonstrate that HLX is functionally
important for AML cells and that targeting HLX can inhibit cellular
growth, decrease clonogenicity, and lead to improved survival in
a murine AML transplantation model. Of note, Hlx heterozygous
mice, which show a 50% reduction of HLX protein levels in BM198 Cancer Cell 22, 194–208, August 14, 2012 ª2012 Elsevier Inc.cells, did not show any noticeable effects on normal hematopoi-
esis, including hematopoietic stem cell functions, such as
capacity for hematopoietic reconstitution and serial transplant-
ability (Figure S4).
Inhibition of HLX Leads to Decreased Cell Cycling,
Increased Cell Death, and Differentiation of AML Cells
and Causes Significant Changes in Gene Expression
To obtain insight into the mechanism of action of HLX inhibition,
we studied the cell biological and molecular consequences of
knockdown of HLX in leukemia cells. We found that HLX down-
regulation in URE cells led to a decrease in viable cells and to
an increase in necrotic cells (Figure 5A). This was accompanied
by a lower number of cells in S phase (p = 0.027) and a higher
number of cells in G0/G1 phase of cell cycle (p = 0.002) (Fig-
ure 5B). In addition, reduction of HLX led to an increased
population of cells expressing lower levels of Kit and higher
levels of Gr-1 and Mac1, indicative of myeloid differentiation
(Figures 5C and 5D). Stimulation with GM-CSF further increased
the number of Mac1- and Gr-1-expressing cells and led to
increased differentiation of AML cells upon sh Hlx treatment in
comparison to control-treated cells, which retained an imma-
ture, leukemic morphology (Figure 5E). This observation shows
that inhibition of HLX can overcome the myeloid differentiation
block of AML cells.
To gain insight into the molecular effects caused by HLX inhi-
bition, we measured gene expression profiles of sh Hlx-trans-
duced URE cells and control shRNA-transduced cells. Leukemia
cells treated with Hlx-directed shRNAs displayed an altered
gene expression pattern, with 392 genes being significantly
differentially expressed (mean difference > 0.5 [log2], p < 0.05)
(Figure 5F). Gene set enrichment analysis (GSEA) showed that
‘‘leukocyte differentiation,’’ ‘‘cell activation,’’ and ‘‘cell prolifera-
tion’’ were among the most significantly affected cellular func-
tions (Figure 5G), which is consistent with the leukemia-inhibitory
effect of HLX reduction in URE cells. We specifically found that
several key genes involved in the regulation of cell cycle and
proliferation, cell death, and myeloid differentiation, were signif-
icantly changed upon HLX downregulation (Figure 5H). We
confirmed differential expression of several genes—namely,
Btg1, FoxO4, Fyn, Gadd45a, RhoB, Trp63, Zfp36l1, Hdac7,
and Pak1—by qRT-PCR (Figure 5I and Figure S5A). We also
found enrichment of genes involved in pathways of other cellular
functions (Figure S5B). Furthermore, we utilized GSEA to
compare the Hlx knockdown data with the molecular signatures
database (MSigDB) (Mootha et al., 2003; Subramanian et al.,
2005) and found negative enrichment of several known
leukemia- and stem cell-related gene signatures (Table S1).
Taken together, these data are consistent with a model that
HLX overexpression leads to activation of a specific transcrip-
tional program in leukemia cells, which affects processes critical
for leukemogenesis such as cell differentiation and proliferation,
and which can at least partially be reversed by inhibition of HLX.
We focused on two downstream genes modulated upon HLX
inhibition in AML cells, Pak1 and Btg1, which have previously
been implicated in the regulation of cell cycle and malignant
proliferation (Ong et al., 2011; Kuo et al., 2003). Knockdown of
PAK1 in KG1a AML cells led to a significant inhibition of cell
proliferation (p < 0.05) and clonogenicity (p < 0.03) (Figure 5J
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Figure 3. HLX Induces a Myelomonocytic Differentiation Block
(A) Representative FACS analysis of GFP+CD34Kit cells after the primary colony-forming assay. Relative percentages of cells in the indicated gates are given
and show a reduction of mature myelomonocytic cells derived from the cells overexpressing HLX.
(B) FACS analysis of cells derived from control-transduced or Hlx-transduced LSK cells after culture in methylcellulose with 25 ng/ml GM-CSF. Relative
percentages of cells are given for each gate and show a lower number of cells expressing mature myelomonocytic markers.
(C) Representative morphology of cells from (B). Cells with immature morphology can be found in the colonies derived from cells transduced with Hlx (indicated
by arrows).
(D) FACS analysis of cells derived from control-transduced or Hlx-transduced LSK cells after culture in methylcellulose with 100 ng/ml M-CSF.
(E) Representative morphology of cells from (D), which confirms a monocytic differentiation block. Cells with immature morphology are indicated by arrows. See
also Figure S3 for additional data.
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Figure 4. HLX Downregulation Inhibits AML
Lentiviruses expressing short hairpins directed against Hlx (sh Hlx) or a control (sh control) were used to downregulate HLX in mouse AML cells (panels A–C) and
human AML cells (sh HLX) (panel D).
(A) Western blotting shows a >80% reduction of HLX protein by shRNA.
(B) Cell proliferation kinetics were determined bymanual cell counts using trypan blue exclusion (n = 3) in sh control cells (white bars) and sh Hlx cells (black bars).
Different time points (days) are indicated. Error bars indicate SD.
(C) Clonogenic assay of URE cells treated with sh control or sh Hlx; 1,000 cells each were cultured inmethylcellulose, andGFP+ colonies were counted. Error bars
indicate SD (n = 3).
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HLX Regulates Early Hematopoiesis and Promotes AMLand Figure S5C), mimicking the effects we had observed by
knockdown of HLX. Similarly, ectopic expression of BTG1 led
to a significant inhibition of cell growth (p < 0.01) and colony-
forming capacity (p < 0.008) of KG1a cells (Figure 5K and Fig-
ure S5D). These findings suggest that downregulation of PAK1
and upregulation of BTG1 are functionally relevant for mediating
the leukemia-inhibitory effects of HLX knockdown.
HLX Is Overexpressed in Patients with AML
To examine whether HLX overexpression plays a role in human
leukemia, we analyzed gene expression data of 354 patients
with AML (Figueroa et al., 2010; Wouters et al., 2009). HLX
was overexpressed in 87% of patients with AML in comparison
to CD34+ cells of healthy donors (Figure 6A). On average,
HLX expression was 2.03-fold higher in patients with AML
(p = 1.9 3 109; Figure 6B). Fifty-four percent (190 of 354) of
patients with AML overexpressed HLX more than 2-fold, with
the range extending up to 6.8-fold overexpression. These results
demonstrate that HLX overexpression is a common feature in
patients with AML. HLX overexpression was found across
different French-American-British (FAB) classification subsets
of AML (Table S2). Of note, highHLX expression was significantly
more frequent in AML with myelomonocytic (M4) and mono-
blastic (M5) morphology, which is consistent with the observed
myelomonocytic differentiation block caused by HLX overex-
pression in vitro.
Increased HLX Expression Correlates with Inferior
Survival
We further sought to examine whether HLX expression levels in
patients were associated with known clinical or molecular
parameters. We analyzed four published data sets of patients
with AML, of whom gene expression and time-to-event data
were available (NCBI GEO accession numbers GSE10358,
GSE12417 [U133A], GSE12417 [U133plus2], and GSE14468)
(Metzeler et al., 2008; Tomasson et al., 2008; Wouters et al.,
2009). Because the lower 25% of patients had HLX expression
levels very similar to CD34+ cells of healthy donors (Figure 6B),
we decided to use the 25th percentile to dichotomize patients
into ‘‘HLX high’’ and ‘‘HLX low’’ expressers. We compared
the overall survival of patients with AML with low versus high
HLX, and observed that in each of the four different data sets,
high HLX expression was associated with inferior overall
survival (Figures S6A–S6D). Overall survival (irrespective of
HLX status) in data sets GSE12417 (U133plus2.0), GSE14468,
and GSE10358 was very similar, with superimposable survival
curves (p = 0.4636, log-rank test; Figure S6E), suggesting that
these cohorts and their clinical outcomes could be combined
for further analyses. The GSE12417 (U133A) data set showed
a worse overall survival outcome compared with the other data
sets (Figure S6F) andwas therefore not included in the combined
analysis. Consistent with the analyses of the individual data(D) Cell proliferation kinetics in suspension culture (top panel) and clonogenicit
MOLM13, right panel). Time points (days) are indicated. Error bars (SD) and stat
(E) Transplantation of URE cells transducedwith sh control or sh Hlx into NSGmice
into NSG mice after sublethal irradiation (250 cGy). Kaplan-Meier curves of overa
also Figure S4 for additional data.sets, the evaluation of the combined set of patients from the
GSE10358, GSE12417 (U133plus2.0), and GSE14468 data
sets (n = 601 total) confirmed that highHLX levels are associated
with inferior overall survival (p = 2.336 3 106 [log-rank]; hazard
ratio [HR] = 0.57 [95% CI: 0.046–0.71]; median survival:
17.05 months [HLX high], ‘‘not reached’’ [HLX low]; 5-year
survival rate: 32.95% [HLX high], 55.85% [HLX low]) (Figure 6C).
To assess whether the impact of HLX expression on overall
survival is independent of known prognostic factors for AML,
we performed multivariate analysis based on the data of the
GSE14468 data set (Figueroa et al., 2010; Wouters et al.,
2009), using a Cox regression model. In this analysis, high HLX
status remained an independent prognostic factor (p = 0.0416;
HR, 1.521) along with FLT3 mutation status (p = 0.0003; HR,
1.925), NPM1 mutation status (p = 0.0006; HR, 0.518), CEBPA
mutation status (p = 0.0371; HR, 0.693), and cytogenetic risk
group (p = 0.0109; HR, 1.382). Of note, the relative blast
percentage in the bone marrow was not correlated with HLX
expression or overall survival (Figures S6G–S6I). The indepen-
dent prognostic role of HLX status led us to hypothesize that it
may provide additional prognostic information for patients who
belong to previously established, molecularly defined subtypes
of AML. We indeed observed that, among patients with FLT3
WT, NPM1 mutations, or CEBPA mutations, high HLX expres-
sion was associated with inferior overall survival (p = 0.0175,
p = 0.0407 and p = 0.0306, respectively) (Figures 6D–6F).An HLX-Dependent Transcriptional Signature Is
Functionally Relevant in Patients with AML
To obtain insight into the molecular consequences of elevated
HLX levels, we overexpressed HLX in sorted murine LSK cells
and performed genomewide transcriptional analysis. We found
that 195 genes were significantly changed, resulting in a clearly
distinguishable expression signature induced by HLX overex-
pression (Figure S6J). Using GSEA, we found enrichment of
known leukemia- and stem cell-related gene signatures, consis-
tent with our previous findings (Table S3).
Next, we tested whether this mouse LSK HLX overexpression
gene set correlated with HLX expression in human patients with
AML. Specifically, we compared the human orthologs of the
mouse gene set to HLX expression levels of patients with AML
in the different cohorts using globaltest (Goeman et al., 2004).
We found a highly significant correlation between the mouse
gene signature and HLX expression in human AML samples
(p = 7.43 3 1023 for GSE14468, p = 2.13 3 1008 for
GSE10358, p = 2.31 3 1006 for GSE12417 [U133plus2.0], and
p = 5.01 3 1010 for GSE12417 [U133A]). Furthermore, we
intersected differentially expressed genes from the HLX overex-
pression or inhibition studies with analogously differentially ex-
pressed genes in ‘‘HLX high’’ versus ‘‘HLX low’’ patients of the
GSE14468 data set, and analyzed these genes for association
with survival. Thereby, wewere able to define anHLX-dependenty (bottom panel) of human AML cells (KG1a, left panel; THP1, middle panel;
istical significance is indicated (t test, n = 4).
. Onemillion (left panel) or 5million cells (right panel) were retroorbitally injected
ll survival of recipient mice are displayed. p values (log-rank) are indicated. See
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Figure 5. Inhibition of HLX Leads to Decreased Cell Cycling, Increased Cell Death, and Differentiation of AML Cells and Causes Significant
Changes in Gene Expression
(A) Relative percentages (± SD) of viable cells (DAPI-negative/Annexin V-negative), apoptotic cells (DAPI-negative/AnnexinV-positive), and necrotic cells (entire
DAPI-positive) in sh control cells (white bars) and sh Hlx cells (black bars). p values are indicated (n = 3).
(B) Cell cycle status of sh control and sh Hlx leukemia cells. Percentages of cells in G0/G1 (white bars), S (gray bars), and G2/M (black bars) phase of cell cycle are
displayed. Statistical significance is indicated (n = 3).
(C and D) Cell surface marker analysis after suspension culture for 3 days. Relative percentages of cells in the indicated gates are given and show a decrease of
immature Kit+ cells and an increase of KitGr1+ cells (C), and an increase of Mac1+ cells (D).
(E) Morphology of cells after treatment with 100 ng/ml recombinant GM-CSF for 3 days. Cells with maturation signs are indicated by arrows.
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with HLX expression status in patients with AML (Figure 6G).
When we dichotomized patients into ‘‘HLX signature high’’
versus ‘‘HLX signature low’’ patients (defined by the genes
of the signature, excluding HLX), we found that ‘‘HLX signa-
ture high’’ patients had significantly inferior overall survival
(p = 0.0089 [log-rank]; HR, 0.66 [95% CI: 0.48–0.90]; median
survival: 17.22 months for HLX signature high, ‘‘not reached’’
for HLX signature low; 5-year survival rate: 34.5% for HLX signa-
ture high, 53.9% for HLX signature low) (Figure 6H).
We subsequently validated the HLX signature in an indepen-
dent cohort of patients, the GSE10358 data set, and found that
the signature correlated strongly (p = 7.8 3 1011) with ‘‘HLX
high’’ versus ‘‘HLX low’’ expression status in these patients
with AML as well (Figure 6I). Furthermore, ‘‘HLX signature
high’’ patients showed a strikingly inferior overall survival (p =
1.89 3 1005 [log-rank]; HR, 0.42 [95% CI: 0.28–0.62]; median
survival: 18.3 months [HLX signature high], ‘‘not reached’’ [HLX
signature low]; 5-year survival rate: 29.0% [HLX signature
high], 67.0% [HLX signature low]) (Figure 6J). Taken together,
these data suggest that elevated HLX levels cause a specific,
functionally critical gene expression signature in human AML.
Interestingly, PAK1 was part of the HLX-induced prognostic
signature. Given our finding that PAK1 mediates the leukemia-
inhibitory effects of HLX knockdown in AML cells (Figure 5J),
we asked whether PAK1 expression levels alone may be func-
tionally relevant in patients with AML. We dichotomized patients
with AML into ‘‘PAK1 high’’ and ‘‘PAK1 low’’ expressers and
analyzed clinical outcome. ‘‘PAK1 high’’ patients showed signif-
icantly inferior overall survival (p = 0.00014 [log-rank]) than did
‘‘PAK1 low’’ patients (median: 17.7 months [PAK1 high] versus
109.1 months [PAK1 low]; 5-year survival rate: 34.0% [PAK1
high] versus 50.5% [PAK1 low]) (Figure S6K). Of note, high
PAK1 expression was associated with inferior overall survival
only in patients of the ‘‘HLX high’’ group (p = 0.0005 [log-rank];
HR, 0.62 (95% CI: 0.48–0.81)); median survival: 15.8 months
[PAK1 high], 42.0 months [PAK1 low]; 5-year survival rate:
29.7% [PAK1 high], 48.1% [PAK1 low]), but not in ‘‘HLX low’’
patients (p = 0.77 ([og-rank]; HR, 1.08 (95% CI: 0.65–1.78]);
5-year survival rate: 55.0% [PAK1 high], 55.0% [PAK1 low])
(Figures S6L and S6M). In addition, PAK1 expression levels
were on average 1.5-fold higher (p = 2.2 3 1016) in ‘‘HLX
high’’ patients compared to ‘‘HLX low’’ patients (Figure S6N),
and HLX and PAK1 expression levels in individual patients
were also significantly correlated (p = 8.83 1015, R = 0.31; Fig-(F) Hierarchical clustering of genes differentially expressed in URE leukemia cells
(G) Enrichment map representation of cellular processes perturbed in leukemia c
circles) connected by edges (green links) denoting the degree of gene set overlap
edge thickness represents the number of genes that overlap between gene s
enrichment of a particular gene set. Groups of functionally related gene sets are c
Figure S5. See Table S1 for additional information.
(H) Select genes altered by HLX inhibition in URE leukemia cells. Upregulated
involvement in regulation of cell cycle-proliferation, cell death, and myeloid diffe
(I) Validation of differential mRNA expression of Btg1 and Pak1. Fold changes (±
qRT-PCR validation is shown in Figure S5.
(J) Short hairpin (shPAK1) or a control (sh control) were used to downregulate HLX
and clonogenicity (right panel) are shown. Error bars indicate SD (n = 4).
(K) Effect of BTG1 overexpression on KG1a proliferation (left panel) and colony fo
PAK1 knockdown and BTG1 overexpression are shown in Figures S5C and S5Dure S6O). Furthermore, experimental overexpression of HLX in
LSK cells led to a significant increase in Pak1mRNA expression
(1.9-fold, p = 0.017; Figure S6P).
DISCUSSION
Utilizing bothmouse and humanmodel systems, we have shown
that the class II homeobox protein HLX affects hematopoietic
stem cell function, as well as clonogenicity and differentiation
of immature hematopoietic progenitor cells. We found that HLX
is significantly overexpressed in the majority of patients with
AML and that high HLX expression levels are independently
associated with inferior clinical outcome. Thereby, our study
identifies HLX as a class II homeobox gene which is critically
involved in the pathogenesis of AML. Our finding that increased
HLX expression correlates with more aggressive disease,
combined with the observation that HLX knockdown results in
an inhibition of growth and clonogenicity of leukemia cells,
further suggest that HLX may be a promising prognostic and
therapeutic target. Future studies evaluating HLX in the context
of different therapies will be required to determine whether
HLX also has predictive relevance.
Many clustered (class I, or HOX) homeobox genes have been
implicated in normal hematopoiesis as well as leukemia, but
much less is known about the role of nonclustered (class II)
homeobox transcription factors (for review, see Argiropoulos
and Humphries, 2007). Several HOX genes are expressed at
high levels in subtypes of AML (Alcalay et al., 2005; Ayton and
Cleary, 2003; Bullinger et al., 2004; Horton et al., 2005). Impor-
tant roles in leukemic transformation have been demonstrated
specifically for several members of the HOX-A and the HOX-B
cluster (Fischbach et al., 2005; Krivtsov et al., 2006; Kroon
et al., 1998; Sauvageau et al., 1997; Somervaille and Cleary,
2006; Thorsteinsdottir et al., 1997). Also, the nonclustered
homeobox gene CDX2 was recently reported to be implicated
in leukemogenesis (Scholl et al., 2007). However, the clinical
significance of these known HOX genes is largely unclear.
Here, we report that expression levels of a homeobox gene are
strongly associated with inferior overall survival in several large,
independent cohorts of patients with AML. Furthermore, the
prognostic value of HLX is a broad phenomenon across several
molecular subsets of patients, and HLX holds up as an indepen-
dent prognostic factor in a multivariate model. Gene expression
analyses upon experimental overexpression and inhibition of
HLX demonstrated that HLX regulates the expression ofupon HLX knockdown. Expression levels are color-coded.
ells upon HLX knockdown. Enriched gene sets are represented as nodes (red
. The node size is proportional to the number of genes in the gene set and the
ets. The color intensity of the nodes indicates the statistical significance of
ircled in gray and labeled. A more comprehensive enrichment map is shown in
genes are shown in red, and downregulated genes are shown in blue. Their
rentiation is indicated.
SD) upon HLX knockdown are shown. (*p < 0.05; **p < 0.01, n = 3). Additional
downstream target PAK1 in human AML cell line KG1a. Proliferation (left panel)
rmation capacity (right panel). Error bars indicate SD (n = 4). Quantification of
.
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Figure 6. HLX Is Overexpressed in Patients with AML and Correlates with Poor Overall Survival
(A) Waterfall plot of relative expression (log2) of HLX of 354 patients with AML in comparison to CD34-enriched bone marrow cells from 11 healthy donors.
(B) Box plot summary of the HLX expression data shown in (A). HLX expression is significantly higher in patients with AML in comparison to CD34+ cells from
healthy donors (p = 1.9 3 109). The median expression values (bold lines), 25th and 75th percentile (bottom and top of box), and the minimum and maximum
(lower and upper whiskers) of both groups are shown. See Table S2 for additional information.
(C) Kaplan-Meier survival plots of overall survival (OS) of patients with high versus low HLX expression in a combined data set of 601 patients with AML
(GSE10358, GSE12417 (U133plus2.0) and GSE14468). Patients with high expression ofHLX show drastically inferior clinical outcome. The p value (log-rank test)
is indicated. Kaplan-Meier plots for all individual data sets are shown in Figures S6A–S6F.
(D–F) Kaplan-Meier survival plots comparing overall survival (OS) of patients with high versus low HLX expression in molecularly defined subsets of AML. High
expression of HLX is associated with significantly inferior clinical outcome in all subsets. p values (log-rank test) are given.
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HLX Regulates Early Hematopoiesis and Promotes AMLa specific subset of genes, and that part of this ‘‘HLX signature’’
is also detectable in patients with AML and discriminates
between patients with poor and favorable clinical outcome.
Taken together, these observations suggest that HLX is a key
regulator of a gene subset critical for AML pathogenesis and
that it may define a previously unrecognized molecular subtype
of AML with distinct biological features and clinical outcome.
We identified PAK1 and BTG1 as two genes downstream of
HLX inmyeloid cells and show thatPAK1 andBTG1 are function-
ally relevant in AML cells. Notably, PAK1 is upregulated in
human patients with AML with high HLX expression, and it is
also part of the HLX-induced core signature that independently
predicts overall survival in patients with AML. Interestingly,
high PAK1 expression itself is associated with inferior overall
survival, but only in patients with highHLX expression, indicating
that there is an interaction of HLX and PAK1with respect to their
impact on overall survival. The correlation of HLX and PAK1
expression levels in the murine HLX knockdown model and in
patients with AML, together with the observed induction of
Pak1 expression upon HLX overexpression in stem cells,
strongly suggest that Pak1 is a downstream target of HLX and
critically mediates, at least in part, the leukemia-promoting
effects of HLX in patients in vivo. Further studies will be required
to determine the exact nature of this regulation, and whether it is
direct or indirect.
Several HOX genes, such as HOXB4, have been reported to
be stimulators of HSC function and expansion (Antonchuk
et al., 2002; Sauvageau et al., 1995). Our data show that HLX
suppresses the function of normal immature HSC and progeni-
tors, but leads to an increase of clonogenicity, as well as
a differentiation block at the level of phenotypically more
mature progenitors. Because the loss of HSC does not seem
to be mediated by induction of apoptosis or necrosis, one may
speculate that HLX exerts this dual role by triggering initial differ-
entiation of HSC and suppression of terminal differentiation at
a more committed progenitor level. Further studies will be
required to understand the molecular basis of this effect.
Although overexpression of HLX led to the formation of myeloid
progenitors with unlimited serial clonogenicity, we so far did not
observe development of leukemia upon transplantation, sug-
gesting that HLX elevation alone may not be sufficient for full
transformation. Like other homeobox genes, Hlx may function
in concert with cofactors (Moens and Selleri, 2006; Pineault
et al., 2004). Such cofactors could confer cell type specificity
to the effects of HLX overexpression and also contribute to
leukemic transformation. It is also possible that increase of
HLX plays a role in leukemia maintenance rather than leukemia
induction.(D) Patients with AML with no detectable mutations of the FLT3 gene.
(E) Patients with AML with mutant NPM1.
(F) Patients with AML with mutant CEBPA.
(G) Heat map of log2-normalized, median-centered gene expression of a 17-gene
status is indicated. Relative gene expression is color-coded (red: high, blue: low
(H) Kaplan-Meier plot comparing overall survival (OS) of ‘‘HLX signature high’’ ve
(log-rank) is indicated.
(I) Heat map of log2-normalized, median-centered gene expression of the ‘‘HLX
(J) Kaplan-Meier survival plot comparing overall survival (OS) of ‘‘HLX signature
The p value (log-rank) is indicated. See also Figure S6 and Table S3 for additionSeveral transcription factors that govern normal hematopoi-
etic differentiation have been implicated in leukemogenesis by
blocking differentiation and promoting self-renewal and clono-
genicity (for review, see Rosenbauer and Tenen, 2007). HLX
may act similar to those factors by establishing a specific gene
expression program in early HSPC, which results in increased
long-term clonogenicity and a differentiation arrest, contributing
to poor clinical outcome. Thus, HLX expression levels may be
utilized to predict clinical outcome and improve risk stratifica-
tion. Finally, inhibition of HLX may be a promising strategy for
treatment of patients with AML.
EXPERIMENTAL PROCEDURES
Mice and Cells
FVB/nJ mice (Ly5.1), C57BL/6J (Ly5.2) mice, and B6.SJL-Ptprca Pepcb/BoyJ
(Pep boy, Ly5.1) and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
used for in vitro assays and in vivo transplantation assays. Mice with targeted
disruption of the upstream regulatory element (URE) of the PU.1 gene have
been previously described (Rosenbauer et al., 2004). All animal experiments
were approved by the Institutional Animal Care and Use Committee of the
Albert Einstein College of Medicine (protocol # 20080109). URE cells were
established and maintained as described previously (Steidl et al., 2006).
Human AML cell lines THP1, MOLM13, and KG1a were cultured under stan-
dard conditions.
Flow Cytometric Analysis and Sorting
Mononuclear cells were purified by lysis of erythrocytes. For analysis and
sorting, we used antibodies directed against CD4[GK1.5], CD8a[53-6.7],
CD19[eBio1D3], Gr-1[RB6-8C5], B220[RA3-6B2], F4/80[BM8], c-kit[ACK2],
Sca-1[D7], CD34[RAM34], CD16/32[93], Flk-2[A2F10], Mac1[M1/70], Ter119
[TER-119], and Thy-1.2[53-2-1]. To distinguish donor from host cells in trans-
planted mice, cells were additionally stained with anti-CD45.1[A20] and
CD45.2[104]. Analysis and sorting were performed using a FACSAria II Special
Order System (BD Biosciences, San Jose, CA). See Supplemental Experi-
mental Procedures for more details.
Lentiviral Vectors and Transduction
For overexpression studies, we introduced the mouse Hlx coding sequence
into the EcoRI site of a pCAD-IRES-GFP lentiviral construct (Steidl et al.,
2007). For BTG1 overexpression, we introduced the human BTG1 coding
sequence into the EcoRI site of the pCAD-IRES-GFP construct. For murine
knockdown studies, we inserted shRNA template oligonucleotides (target
sense strand-loop-target antisense strand-TTTTT) into the pSIH1-H1-copGFP
shRNA vector (System Biosciences, Mountain View, CA). For human
knockdown studies, we utilized the pGIPZ system from Open Biosystems
(Huntsville, AL). See Supplemental Experimental Procedures for sequence
information. For knockdown of PAK1, we utilized the plko.1-puro vector
system (Sigma) with nonsilencing control or human PAK1 target. Lentiviral
particles were produced utilizing 293T cells and were concentrated by
ultracentrifugation. For overexpression studies, we treated sorted LinKit+
cells fromWT C57BL/6J (Ly5.2) BM (for in vivo assays) or LinKit+Sca-1+ cells
from WT FVB/nJ BM (for in vitro assays) with control virus or Hlx virus. In brief,‘‘HLX signature’’ in patients with AML of the GSE14468 cohort.HLX expression
).
rsus ‘‘HLX signature low’’ AML patients of the GSE14468 cohort. The p value
signature’’ in AML patients of the GSE10358 cohort.
high’’ versus ‘‘HLX signature low’’ patients with AML of the GSE10358 cohort.
al information.
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8 mg/ml polybrene. Twenty-four hours after transduction, cells were washed
with PBS and then used for experiments. After 40 hr, transduction efficiency
was determined by flow cytometry. For knockdown studies, cells were incu-
bated with short-hairpin-containing lentivirus for 24 hr. GFP+ cells were sorted
using a FACS Aria II sorter (BD Biosciences) and used for experiments.
Quantitative Real-Time PCR
We extracted total RNA from FACS-sorted cells or cultured cells using RNeasy
Micro kit (QIAGEN, Valencia, CA) and synthesized cDNA by Superscript II
reverse transcriptase (Invitrogen, Carlsbad, CA). We performed real-time
PCR using an iQ5 real-time PCR detection system (BIO-RAD, Hercules, CA)
with 1 cycle of 50C (2 min) and 95C (10 min) followed by 40 cycles of 95C
(15 sec) and 60C (1 min) using Power SYBR Green PCR master mix
(AB, Carlsbad, CA) (see Supplemental Experimental Procedures for primer
sequences).
Western Blotting
See Supplemental Experimental Procedures.
Cell Proliferation, Cell Cycle, and Apoptosis Assays
See Supplemental Experimental Procedures.
Colony Formation Assays and Serial Replating Assays
Assays were performed in MethoCult M3434 (Stem Cell Technologies,
Vancouver, BC) containing IL-3, IL-6, SCF, and EPO or in MethoCult M3234
supplemented with M-CSF or GM-CSF as previously described (Higuchi
et al., 2002; Huntly et al., 2004; Will et al., 2009). GFP+ colonies were scored
8–10 days after plating using an AXIOVERT 200M microscope (Zeiss, Maple
Grove, MN). After scoring, we resorted GFP+ cells after each round and then
proceeded with serial replating assays. Cells were replated and colonies
were again scored after 10–14 days.
Transplantation Assays
For HLX overexpression studies, 5 3 104 lentivirus-transduced LinKit+ cells
(Ly5.2) together with 2.5 3 105 spleen cells from congenic WT recipients
(Ly5.1) were transplanted into lethally irradiated age-matched congenic WT
recipients (Ly5.1) by retroorbital vein injection. Total body irradiation was
delivered in a single dose of 950 cGy using a Shepherd 6810 sealed-source
137Cs irradiator.
Micorarray Experiments and Analysis
RNA was extracted from sorted GFP+ cells utilizing the RNeasy Micro Kit
(QIAGEN). After evaluation of the quality of RNA with an Agilent2100
Bioanalyzer, total RNA was used for amplification utilizing the Nugen Ovation
pico WTA system according to the manufacturer’s instructions. After labeling
with the GeneChip WT terminal labeling kit (Affymetrix), labeled cRNA of each
individual sample was hybridized to AffymetrixMouse Gene 1.0STmicroarrays
(Affymetrix), stained, and scanned by GeneChip Scanner 3000 7G system
(Affymetrix) according to standard protocols. For data analysis, we utilized
Multiple Experiment Viewer v.4 pilot2 (Saeed et al., 2006), DAVID bioinfor-
matics tool (Huang et al., 2009a, 2009b), Enrichment Map Cytoscape plugin
(Cline et al., 2007; Merico et al., 2010), and Gene Set Enrichment Analysis
v2.0 (GSEA) (Mootha et al., 2003; Subramanian et al., 2005). See Supplemental
Experimental Procedures for details.
Data Sets and Statistical Analysis
We analyzed the publicly available gene expression data sets with accession
numbers GSE12417 (training set U133A and U133B; test set U133plus2.0),
GSE14468, and GSE10358 (http://www.ncbi.nlm.nih.gov/geo/). Clinical out-
come and mutational data for the GSE10358 data set were obtained from
a recent study of the same group (Ley et al., 2010). Analyses of the gene
expression profiles from GSE14468, GSE12417 training set, and GSE10358
were performed based on published (Gentles et al., 2010) and publicly avail-
able MAS5 files (GSE24006) with reanalyzed data. For analysis of the test
set of the GSE12417 data set, CEL files were processed using GenePattern
(Broad Institute, Cambridge MA) for normalization (ExpressionFileCreator
algorithm). We utilized GraphPad Prism 5.0, R/Bioconductor sva package206 Cancer Cell 22, 194–208, August 14, 2012 ª2012 Elsevier Inc.(R package version 3.2.0) (Leek et al., 2012), and SPSS 18.0 statistical
package for further analyses. See Supplemental Experimental Procedures
for details.
Signature Generation and Calculation of Signature Scores
We utilized dChip (http://biosun1.harvard.edu/complab/dchip/), SAM (signifi-
cance analysis of microarrays), as well as R/Bioconductor globaltest (Goeman
et al., 2004) for signature identification, followed by calculation of signature
scores. See Supplemental Experimental Procedures for details.
ACCESSION NUMBER
Complete array data are available in the Gene Expression Omnibus (GEO) of
NCBI (Edgar et al., 2002), accession number GSE27947.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.06.027.
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